Skip to main content
. Author manuscript; available in PMC: 2014 Jun 28.
Published in final edited form as: J Control Release. 2013 Apr 6;168(3):251–261. doi: 10.1016/j.jconrel.2013.03.020

Figure 5.

Figure 5

In vitrodelivery of anti-miR-155-Lac-GLN. The results are the mean of three repeats. Error bars stand for standard deviations. A. HepG2 cells were transfected with anti-miR-155 containing Lac-GLN at the concentration of 100 nM for 4 hr, and miR-155 expression was evaluated 48 hr after transfection. B. Evaluation of different concentrations of anti-miR-155 treatments on miR-155 expression. HepG2 cells were transfected with 100 nM or 200 nM anti-miR-155 containing Lipofectamine2000 and Lac-GLN for 4 hr, and miR-155 expression was evaluated 48 hr after transfection. C. Evaluation of miR-155 targeting gene expressions. C/EBPβ and FOXP3 gene expression were evaluated 48 hr after HepG2 cells were transfected with positive control or Lac-GLN containing 100 nM and 200 nM anti-miR-155.